Shandong Keyuan Pharmaceutical Co., Ltd. (SHE:301281)
China · Delayed Price · Currency is CNY 48.82
+2.38 (5.12%)
At close: Sep 14, 2026
SHE:301281 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 501.86 | 395.19 | 457.46 | 445.94 | 442.31 | 419.67 |
Other Revenue | -0.04 | 3.04 | 6.26 | 1.64 | 0.55 | 1.22 |
| 501.83 | 398.23 | 463.72 | 447.58 | 442.87 | 420.89 | |
Revenue Growth | 10.43% | -14.12% | 3.60% | 1.06% | 5.22% | 14.67% |
Cost of Revenue | 242.76 | 201.9 | 266.76 | 240.86 | 264.82 | 246.14 |
Gross Profit | 259.07 | 196.33 | 196.96 | 206.73 | 178.04 | 174.75 |
Selling, General & Admin | 163.68 | 131.53 | 116.12 | 99.72 | 56.03 | 63.1 |
Research & Development | 34.15 | 42.35 | 35.82 | 43.86 | 26.97 | 24.43 |
Other Operating Expenses | 1.77 | 2.55 | 4.19 | 4.36 | 5.3 | 4.47 |
Operating Expenses | 199.97 | 178.21 | 156.42 | 148.25 | 89.14 | 92.11 |
Operating Income | 59.1 | 18.12 | 40.54 | 58.48 | 88.91 | 82.64 |
Interest Expense | - | -0.02 | -0.04 | - | - | - |
Interest & Investment Income | 3.12 | 7.02 | 15.4 | 15.97 | 1.33 | 0.96 |
Currency Exchange Gain (Loss) | -0.47 | 0.04 | -0.59 | 1.15 | 1.55 | -1.11 |
Other Non Operating Income (Expenses) | -2.18 | 0.07 | -2.03 | 0.09 | -0.32 | 0.05 |
EBT Excluding Unusual Items | 59.58 | 25.24 | 53.29 | 75.7 | 91.47 | 82.55 |
Impairment of Goodwill | -0.8 | -0.8 | - | - | - | - |
Gain (Loss) on Sale of Investments | -1.05 | -1.16 | 0.8 | 0.54 | - | - |
Gain (Loss) on Sale of Assets | -0.22 | -0.26 | -0.84 | 0.04 | 0.37 | -0.04 |
Asset Writedown | -3.8 | - | - | - | - | - |
Legal Settlements | -16.11 | -16.11 | -0.14 | - | - | - |
Other Unusual Items | 8.07 | 9.87 | 12.61 | 3.45 | 6.47 | 7.41 |
Pretax Income | 45.67 | 16.78 | 65.71 | 79.74 | 98.3 | 89.92 |
Income Tax Expense | 7.46 | 0.4 | 5.44 | 2.7 | 7.02 | 11.75 |
Earnings From Continuing Operations | 38.21 | 16.38 | 60.27 | 77.04 | 91.28 | 78.17 |
Minority Interest in Earnings | 0.36 | 0.18 | 0.18 | - | - | - |
Net Income | 38.56 | 16.55 | 60.45 | 77.04 | 91.28 | 78.17 |
Net Income to Common | 38.56 | 16.55 | 60.45 | 77.04 | 91.28 | 78.17 |
Net Income Growth | -42.48% | -72.62% | -21.54% | -15.60% | 16.77% | 13.87% |
Shares Outstanding (Basic) | 110 | 110 | 108 | 101 | 81 | 81 |
Shares Outstanding (Diluted) | 110 | 110 | 108 | 101 | 81 | 81 |
Shares Change | 2.24% | 2.23% | 6.49% | 24.38% | 0.53% | -0.47% |
EPS (Basic) | 0.35 | 0.15 | 0.56 | 0.76 | 1.12 | 0.96 |
EPS (Diluted) | 0.35 | 0.15 | 0.56 | 0.76 | 1.12 | 0.96 |
EPS Growth | -43.74% | -73.21% | -26.32% | -32.14% | 16.15% | 14.40% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | -50.79 | -93.58 | -356.9 | -33.12 | 84.75 | 31.83 |
Free Cash Flow Per Share | -0.46 | -0.85 | -3.31 | -0.33 | 1.04 | 0.39 |
Dividend Per Share | 0.050 | 0.050 | 0.200 | 0.300 | 0.286 | - |
Dividend Growth | -75.00% | -75.00% | -33.33% | 5.00% | - | - |
Gross Margin | 51.62% | 49.30% | 42.47% | 46.19% | 40.20% | 41.52% |
Operating Margin | 11.78% | 4.55% | 8.74% | 13.06% | 20.08% | 19.63% |
Profit Margin | 7.68% | 4.16% | 13.04% | 17.21% | 20.61% | 18.57% |
Free Cash Flow Margin | -10.12% | -23.50% | -76.96% | -7.40% | 19.14% | 7.56% |
EBITDA | 110.92 | 65.78 | 87.4 | 107.43 | 122.54 | 109.5 |
EBITDA Margin | 22.10% | 16.52% | 18.85% | 24.00% | 27.67% | 26.02% |
D&A For EBITDA | 51.82 | 47.67 | 46.86 | 48.95 | 33.63 | 26.86 |
EBIT | 59.1 | 18.12 | 40.54 | 58.48 | 88.91 | 82.64 |
EBIT Margin | 11.78% | 4.55% | 8.74% | 13.06% | 20.08% | 19.63% |
Effective Tax Rate | 16.34% | 2.39% | 8.27% | 3.38% | 7.14% | 13.06% |
Revenue as Reported | 170.36 | 398.23 | 463.72 | 447.58 | 442.87 | 420.89 |
Advertising Expenses | - | 4.09 | 4.03 | 1.89 | - | - |